AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12122551 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg folic acid
Number of subjects: 70
Study 12122551 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg folic acid
Number of subjects: 70
Study 12122551 — intervention group
Group type: COMPARATOR
Intervention: Unfortified breakfast cereal (placebo)
Number of subjects: 70
Study 9523035 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prescribed rectification of vitamins C and E at adequacy of other micronutrients
Number of subjects: 0
Study 9523035 — intervention group
Group type: COMPARATOR
Intervention: Randomized exclusive supplementation of β-carotene ± vitamin A or E
Number of subjects: 0
Study 9523035 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized intervention with synchronous rectification of vitamins A+C+E+B + minerals
Number of subjects: 0
Study 9523035 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin E supplements
Number of subjects: 0
Study 9523035 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma values for primary prevention
Number of subjects: 0
Study 7883280 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 50
Study 7883280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 50
Study 31177899 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation (led by physiotherapist)
Number of subjects: 180
Study 31177899 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised rehabilitation
Number of subjects: 180
Study 29625176 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 sachets of Salovum®
Number of subjects: 40
Study 29625176 — intervention group
Group type: COMPARATOR
Intervention: 2 sachets of Salovum®
Number of subjects: 40
Study 29625176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (2 and 4 sachets of Salovum®)
Number of subjects: 40
Study 26944275 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 2399
Study 26944275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study 25139288 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad Pendulum (QP)
Number of subjects: 35
Study 25139288 — intervention group
Group type: COMPARATOR
Intervention: Segmented Pendulum (SP)
Number of subjects: 35
Study 21404370 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with 6- to 8-mm FWHM filters
Number of subjects: 18
Study 21404370 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with larger filters
Number of subjects: 18
Study 21404370 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with small and large filters
Number of subjects: 18
Study 19132976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 0
Study 19132976 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 0
Study 19132976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16448722 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan at baseline
Number of subjects: 22
Study 16448722 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan at follow-up
Number of subjects: 22
Study 16448722 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 22
Study 15485475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg kg(‐1) in fruit juice
Number of subjects: 16
Study 15485475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg kg(‐1) in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Number of subjects: 16
Study 15485475 — intervention group
Group type: COMPARATOR
Intervention: Methionine-free fruit juice (placebo)
Number of subjects: 16
Study 11568905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine administration
Number of subjects: 11
Study 9623632 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine (T II)
Number of subjects: 10
Study 9623632 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g branched-chain amino acids (BCAA) (T III)
Number of subjects: 10
Study 9623632 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g tyrosine (TYR) (T IV)
Number of subjects: 10
Study 9623632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (T I)
Number of subjects: 10
Study 8209277 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy following surgical resection for stages I, II, and IIIA disease
Number of subjects: 0
Study 8209277 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for locally advanced stages IIIA and IIIB disease
Number of subjects: 0
Study 8209277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for advanced stage IV disease
Number of subjects: 0
Study 8209277 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic response modifiers (interferons, interleukins, colony-stimulating factors, monoclonal antibodies)
Number of subjects: 0
Study 3361457 — intervention group
Group type: EXPERIMENTAL
Intervention: Slab foam cushions (N = 26)
Number of subjects: 62
Study 3361457 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foam cushions (N = 26)
Number of subjects: 62
Study 29956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study 29956398 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 29956398 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise (HIIT and MICT)
Number of subjects: 28
Study 28590898 — intervention group
Group type: COMPARATOR
Intervention: Conventional hearing aids (HA)
Number of subjects: 55
Study 28590898 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-wear, deep fit hearing aids (EWHA)
Number of subjects: 55
Study 28590898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids with sound generator (HA+SG)
Number of subjects: 55
Study 26624886 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 intervention
Number of subjects: 443
Study 24003041 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN; 5 mg/24 hours) for 7 days
Number of subjects: 41
Study 24003041 — intervention group
Group type: COMPARATOR
Intervention: None (control group, blinding under gauze dressing)
Number of subjects: 41
Study 21410294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg with rifampicin 600 mg/day (Study A)
Number of subjects: 34
Study 21410294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg with itraconazole 200 mg/day (Study B)
Number of subjects: 34
Study 18243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) for 6 months
Number of subjects: 45
Study 18243282 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 45
Study 18243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI)
Number of subjects: 45
Study 15258603 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact tonometer (NCT)
Number of subjects: 170
Study 15258603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular blood flow tonometer (OBFT)
Number of subjects: 170
Study 15258603 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 170
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg OD losartan (LOS)
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg OD telmisartan (TEL)
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg OD losartan (LOS) + 20 mg OD lisinopril
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg OD telmisartan (TEL) + 20 mg OD lisinopril
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg OD losartan (LOS)
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg BID losartan (LOS)
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg OD telmisartan (TEL)
Number of subjects: 30
Study 12511526 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg BID telmisartan (TEL)
Number of subjects: 30
Study 10886114 — intervention group
Group type: EXPERIMENTAL
Intervention: SFTX6c (5 pmol min‐1)
Number of subjects: 8
Study 10886114 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐3020 (50 pmol min‐1)
Number of subjects: 8
Study 8927672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (selective serotonin reuptake inhibitor)
Number of subjects: 0
Study 8927672 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (tricyclic antidepressant)
Number of subjects: 0
Study 1797487 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB10
Number of subjects: 7
Study 1797487 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB28
Number of subjects: 7
Study 1797487 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB9GluB27
Number of subjects: 7
Study 1797487 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 7
Study 6348995 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 200 micrograms salbutamol followed immediately by 100 micrograms beclomethasone dipropionate
Number of subjects: 25
Study 6348995 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of 200 micrograms salbutamol followed by 100 micrograms beclomethasone dipropionate after a timed interval of more than five minutes
Number of subjects: 25
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab 100 mg
Number of subjects: 350
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab 25 mg
Number of subjects: 350
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab 200 mg
Number of subjects: 350
Study 30653843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab (all doses)
Number of subjects: 350
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab (100 mg)
Number of subjects: 350
Study 30653843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Number of subjects: 350
Study 30463826 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of methotrexate
Number of subjects: 160
Study 30463826 — intervention group
Group type: COMPARATOR
Intervention: Local administration of methotrexate
Number of subjects: 160
Study 25944814 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective reporting of visual aura symptoms
Number of subjects: 267
Study 25944814 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective reporting of nonvisual aura symptoms
Number of subjects: 267
Study 25944814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective recording of migraine attacks
Number of subjects: 267
Study 25944814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective recording of nausea
Number of subjects: 267
Study 25944814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective recording of phonophobia and photophobia
Number of subjects: 267
Study 24905427 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) for 12 weeks (36 sessions)
Number of subjects: 60
Study 24905427 — intervention group
Group type: COMPARATOR
Intervention: No attention control group (CG)
Number of subjects: 60
Study 26753217 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Patterned Sensory Enhancement (live-PSE)
Number of subjects: 24
Study 26753217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise instruction with live-PSE
Number of subjects: 24
Study 26753217 — intervention group
Group type: COMPARATOR
Intervention: Exercise instruction alone (control)
Number of subjects: 24
Study 26753217 — intervention group
Group type: EXPERIMENTAL
Intervention: Logbook comments during live-PSE
Number of subjects: 24
Study 20729533 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 40
Study 20729533 — intervention group
Group type: COMPARATOR
Intervention: Isolated left ventricular pacing
Number of subjects: 40
Study 17679559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium with glucose monohydrate and sorbitol via Handihaler
Number of subjects: 0
Study 17679559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium via Handihaler
Number of subjects: 0
Study 17679559 — intervention group
Group type: COMPARATOR
Intervention: Intal Spincaps via Spinhaler
Number of subjects: 0
Study 15157261 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water ingested 30 minutes before blood donation
Number of subjects: 80
Study 11826814 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 1200
Study 11826814 — intervention group
Group type: COMPARATOR
Intervention: Monitoring by family practitioners
Number of subjects: 1200
Study 11826814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients trained in INR self-management
Number of subjects: 1200
Study 9742716 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 7762198 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous infrared laser radiation
Number of subjects: 0
Study 2742942 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) 10 mg oral test dose
Number of subjects: 12
Study 2742942 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) 5 mg orally twice daily for 7 days
Number of subjects: 12
Study 2742942 — intervention group
Group type: COMPARATOR
Intervention: Reduced Haloperidol (RHAL) 10 mg oral test dose
Number of subjects: 12
Study 2742942 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) and Reduced Haloperidol (RHAL)
Number of subjects: 12
Study 810265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (NP)
Number of subjects: 26
Study 810265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 26
Study 29223557 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d plus ω‐3 fatty acids 4 g/d (ROSUMEGA group)
Number of subjects: 201
Study 29223557 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 20 mg/d (rosuvastatin group)
Number of subjects: 201
Study 27769209 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral social facilitation treatment (FBSFT), 17 weekly sessions at the OOC.
Number of subjects: 120
Study 27769209 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (treatment as usual, TAU), monthly counselling sessions with primary health care nurse.
Number of subjects: 120
Study 24795142 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 607
Study 24795142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 23276563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodistention plus bladder training (HD plus BT)
Number of subjects: 70
Study 23276563 — intervention group
Group type: COMPARATOR
Intervention: Hydrodistention (HD)
Number of subjects: 70
Study 20133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR therapy
Number of subjects: 0
Study 20133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational predictive molecular markers
Number of subjects: 0
Study 20133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials
Number of subjects: 0
Study 18332845 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day
Number of subjects: 0
Study 18332845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15973347 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 30 days
Number of subjects: 0
Study 15973347 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12641541 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (0.2 Iu kg‐1) and vitamin C (1-g daily)
Number of subjects: 20
Study 12641541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11043699 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH children (intervention group)
Number of subjects: 5106
Study 8653152 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 25
Study 8653152 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 1947866 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment with community care
Number of subjects: 50
Study 6664681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62
Study 6664681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock transcutaneous nerve stimulation)
Number of subjects: 62
Study 31930895 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping at three yin meridians of wrist combined with rehabilitation training
Number of subjects: 72
Study 31930895 — intervention group
Group type: COMPARATOR
Intervention: Simple rehabilitation training
Number of subjects: 72
Study 30334877 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 398
Study 27333261 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC+ (additional smoking cessation advice for 3 months)
Number of subjects: 39
Study 27333261 — intervention group
Group type: COMPARATOR
Intervention: ABC (brief advice and subsidized nicotine replacement therapy)
Number of subjects: 39
Study 27333261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ABC and ABC+
Number of subjects: 39
Study 27296663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention (PI)
Number of subjects: 3000
Study 27296663 — intervention group
Group type: EXPERIMENTAL
Intervention: Student intervention (SI)
Number of subjects: 3000
Study 27296663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (CI)
Number of subjects: 3000
Study 27296663 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 3000
Study 25148255 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin induction therapy
Number of subjects: 99
Study 22432932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1210
Study 22432932 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1210
Study 19914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 0
Study 19914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy alone
Number of subjects: 0
Study 19914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with adjuvant therapy
Number of subjects: 0
Study 19914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy
Number of subjects: 0
Study 19914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in staging methods, surgical technique, radiotherapy technique, and chemotherapy regime
Number of subjects: 0
Study 17324220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 240 mg
Number of subjects: 15
Study 17324220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15644624 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg moclobemide daily for 6 months
Number of subjects: 90
Study 15644624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11872193 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated decisions
Number of subjects: 53
Study 11872193 — intervention group
Group type: COMPARATOR
Intervention: Clinicians' decisions
Number of subjects: 53
Study 9571274 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields soaked in trifluridine (TFT) for at least 30 minutes preoperatively.
Number of subjects: 11
Study 9571274 — intervention group
Group type: COMPARATOR
Intervention: Control group received drops of TFT only.
Number of subjects: 11
Study 7890499 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal eyes (without ROP residua)
Number of subjects: 1694
Study 7890499 — intervention group
Group type: COMPARATOR
Intervention: Eyes with retinal residua of ROP
Number of subjects: 1694
Study 7890499 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acuity comparison
Number of subjects: 1694
Study 3448228 — intervention group
Group type: EXPERIMENTAL
Intervention: DRAMS scheme (n = 34)
Number of subjects: 104
Study 3448228 — intervention group
Group type: COMPARATOR
Intervention: Simple advice only (n = 32)
Number of subjects: 104
Study 3448228 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group (n = 38)
Number of subjects: 104
Study 3448228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample as a whole
Number of subjects: 104
Study 29144805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily (SITA)
Number of subjects: 30
Study 29144805 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone (CON)
Number of subjects: 30
Study 27511501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral with enteral immunonutrition (ENIN)
Number of subjects: 41
Study 27511501 — intervention group
Group type: COMPARATOR
Intervention: Enteral only (EN)
Number of subjects: 41
Study 25022781 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction trials (experimental condition)
Number of subjects: 0
Study 25022781 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning trials (experimental condition)
Number of subjects: 0
Study 25022781 — intervention group
Group type: COMPARATOR
Intervention: Filler task (control condition)
Number of subjects: 0
Study 22869627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeper stretch program (n = 30)
Number of subjects: 62
Study 22869627 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 62
Study 22869627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant side
Number of subjects: 62
Study 21029621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography ≤ 24 h after randomization)
Number of subjects: 815
Study 21029621 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography ≥ 36 h after randomization)
Number of subjects: 815